Atlas Trials

Clinical Investigation of Erlotinib as an HCV Entry Inhibitor

Clinical trial NCT01835938 · UNKNOWN

Trial details

NCT number
NCT01835938
Sponsor
University Hospital, Strasbourg, France
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Chronic Hepatitis C InfectionHCV Genotype 1b
Start date
2013-05-01
Primary completion
2015-05-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.